coronaviru
adenoviru
respiratori
syncyti
viru
frequent
caus
acut
pharyng
viral
caus
acut
pharyng
includ
coxsackieviru
echoviru
herp
simplex
viru
epsteinbarr
viru
frequent
caus
acut
pharyng
often
accompani
clinic
find
infecti
mononucleosi
eg
splenomegali
gener
lymphadenopathi
system
infect
viral
agent
includ
cytomegaloviru
rubella
viru
measl
viru
may
associ
acut
pharyng
ga
common
bacteri
caus
acut
pharyng
account
case
acut
pharyng
children
bacteria
also
caus
acut
pharyng
howev
includ
group
c
g
betahemolyt
streptococci
corynebacterium
diphtheria
arcanobacterium
haemolyticum
rare
caus
acut
pharyng
particularli
teenag
neisseria
gonorrhoea
occasion
caus
acut
pharyng
sexual
activ
adolesc
bacteria
francisella
tularensi
yersinia
enterocolitica
mix
infect
anaerob
bacteria
eg
vincent
angina
rare
caus
acut
pharyng
chlamydia
pneumonia
mycoplasma
pneumonia
implic
caus
acut
pharyng
particularli
adult
although
bacteria
staphylococcu
aureu
haemophilu
influenza
streptococcu
pneumonia
cultur
frequent
throat
children
acut
pharyng
etiolog
role
diseas
establish
case
pharyng
occur
colder
month
year
respiratori
virus
eg
rhinoviru
coronaviru
influenza
viru
adenoviru
preval
spread
among
famili
member
home
promin
featur
epidemiolog
agent
children
major
reservoir
infect
group
betahemolyt
streptococc
pharyng
primarili
diseas
children
age
temper
climat
usual
occur
winter
earli
spring
incid
gonococc
pharyng
highest
among
older
adolesc
young
adult
usual
rout
infect
orogenit
sexual
contact
infect
sexual
partner
sexual
abus
must
strongli
consid
n
gonorrhoea
isol
pharynx
prepubert
child
widespread
immun
diphtheria
toxoid
made
diphtheria
rare
diseas
unit
state
fewer
five
case
report
annual
recent
year
group
c
g
betahemolyt
streptococci
caus
acut
pharyng
clinic
featur
similar
group
betahemolyt
streptococc
pharyng
group
c
streptococcu
rel
common
caus
acut
pharyng
among
colleg
student
adult
evalu
emerg
depart
group
c
streptococcu
also
caus
epidem
foodborn
pharyng
famili
school
outbreak
group
c
streptococc
pharyng
relat
ingest
contamin
food
product
unpasteur
cow
milk
describ
although
sever
welldocu
foodborn
outbreak
group
g
streptococc
pharyng
etiolog
role
group
g
streptococcu
acut
endem
pharyng
unclear
communitywid
respiratori
outbreak
group
g
streptococc
pharyng
pediatr
popul
describ
group
g
streptococcu
isol
consecut
children
acut
pharyng
seen
privat
pediatr
offic
result
dna
fingerprint
group
g
streptococcu
isol
suggest
strain
role
group
c
g
streptococci
acut
pharyng
may
underestim
sever
reason
anaerob
incub
increas
yield
organ
mani
laboratori
use
anaerob
incub
routin
throat
cultur
addit
mani
group
c
g
streptococci
bacitracin
resist
laboratori
may
report
bacitracinsensit
streptococci
consist
ga
mani
group
c
g
streptococci
would
miss
final
mani
clinician
longer
perform
throat
cultur
instead
reli
sole
rapid
antigen
detect
test
radt
group
c
g
streptococci
would
identifi
radt
ga
acut
group
betahemolyt
streptococc
pharyng
certain
clinic
characterist
epidemiolog
pattern
tabl
patient
group
betahemolyt
streptococc
pharyng
commonli
present
sore
throat
gener
sudden
onset
sever
pain
swallow
fever
headach
nausea
vomit
abdomin
pain
also
may
present
examin
patient
typic
tonsillopharyng
erythema
without
exud
tender
enlarg
anterior
cervic
lymph
node
find
includ
beefi
red
swollen
uvula
petechia
palat
excori
nare
especi
infant
scarlitiniform
rash
none
find
specif
group
betahemolyt
streptococc
pharyng
mani
patient
streptococc
pharyng
exhibit
sign
symptom
milder
classic
case
ill
patient
bona
fide
group
betahemolyt
streptococc
pharyng
wherea
other
mere
colon
ga
pharyng
result
intercurr
viral
ill
scarlet
fever
upper
respiratori
tract
infect
associ
characterist
rash
caus
infect
pyrogen
exotoxin
erythrogen
toxin
produc
ga
individu
antitoxin
antibodi
scarlet
fever
encount
less
commonli
less
virul
past
incid
cyclic
depend
preval
toxinproduc
strain
immun
statu
popul
mode
tran
rash
scarlet
fever
appear
within
hour
onset
symptom
although
may
appear
first
sign
ill
rash
often
begin
around
neck
spread
trunk
extrem
diffus
fine
papular
erythemat
erupt
produc
bright
red
discolor
skin
blanch
pressur
involv
often
intens
along
creas
elbow
axilla
groin
involv
skin
goosepimpl
appear
feel
rough
face
usual
spare
although
cheek
may
erythemat
pallor
around
mouth
day
rash
begin
fade
follow
desquam
first
face
progress
downward
often
resembl
seen
mild
sunburn
occasion
sheetlik
desquam
may
occur
around
free
margin
fingernail
palm
sole
examin
pharynx
patient
scarlet
fever
reveal
essenti
find
group
betahemolyt
streptococc
pharyng
addit
tongu
usual
coat
papilla
swollen
desquam
redden
papilla
promin
give
tongu
strawberri
appear
absenc
fever
presenc
clinic
featur
conjunct
cough
hoars
coryza
anterior
stomat
discret
ulcer
lesion
viral
exanthem
diarrhea
suggest
viral
etiolog
rather
ga
acut
pharyng
caus
adenoviru
typic
associ
fever
erythema
pharynx
enlarg
tonsil
exud
enlarg
cervic
lymph
node
adenovir
pharyng
may
associ
conjunct
refer
pharyngoconjunctiv
fever
pharyng
pharyngoconjunctiv
fever
persist
day
conjunct
persist
day
resolv
spontan
outbreak
pharyngoconjunctiv
fever
associ
transmiss
swim
pool
widespread
epidem
sporad
case
also
occur
enterovirus
coxsackieviru
echoviru
newer
enterovirus
caus
acut
pharyng
especi
summer
earli
fall
pharynx
may
erythemat
tonsillar
exud
cervic
adenopathi
unusu
fever
may
promin
resolut
usual
occur
within
day
herpangina
specif
syndrom
caus
coxsackieviru
b
echovirus
character
fever
pain
discret
graywhit
papulovesicular
lesion
erythemat
base
posterior
oropharynx
lesion
becom
ulcer
usual
resolv
within
day
handfootmouth
diseas
specif
syndrom
caus
coxsackieviru
character
pain
vesicl
ulcer
throughout
oropharynx
associ
vesicl
palm
sole
sometim
trunk
extrem
lesion
usual
resolv
within
day
primari
oral
herp
simplex
viru
infect
usual
occur
young
children
typic
produc
acut
gingivostomat
associ
ulcer
vesicular
lesion
throughout
anterior
mouth
includ
lip
spare
posterior
pharynx
gingivostomat
last
week
often
associ
high
fever
pain
may
intens
oral
intak
fluid
may
impair
lead
dehydr
herp
simplex
viru
also
produc
mild
pharyng
adolesc
adult
may
may
associ
typic
ulcer
vesicular
lesion
acut
pharyng
common
find
adolesc
young
adult
infecti
mononucleosi
caus
epsteinbarr
viru
pharyng
infecti
mononucleosi
sever
clinic
find
virtual
ident
group
betahemolyt
streptococc
pharyng
gener
lymphadenopathi
hepatosplenomegali
also
may
present
howev
fever
pharyng
typic
last
week
lymphadenopathi
hepatosplenomegali
resolv
week
laboratori
find
includ
presenc
atyp
lymphocytosi
heterphil
antibodi
specif
antibodi
epsteinbarr
viru
antigen
acut
pharyng
caus
haemolyticum
may
close
resembl
group
betahemolyt
streptococc
pharyng
includ
presenc
scarlitiniform
rash
mani
patient
rare
case
haemolyticum
produc
membran
pharyng
confus
diphtheria
pharyng
diphtheria
character
grayish
brown
pseudomembran
may
limit
one
tonsil
may
extend
wide
involv
nare
uvula
soft
palat
pharynx
larynx
tracheobronchi
tree
involv
tracheobronchi
tree
may
lead
lifethreaten
respiratori
obstruct
soft
tissu
edema
promin
cervic
subment
lymphadenopathi
may
creat
bullneck
appear
decis
perform
microbiolog
test
patient
present
acut
pharyng
base
clinic
epidemiolog
characterist
ill
see
tabl
histori
close
contact
welldocu
case
group
betahemolyt
streptococc
pharyng
high
preval
group
betahemolyt
streptococc
infect
commun
also
may
help
test
usual
need
perform
patient
acut
pharyng
whose
clinic
epidemiolog
featur
suggest
ga
etiolog
select
use
diagnost
studi
ga
increas
proport
posit
test
result
also
percentag
patient
posit
test
truli
infect
rather
mere
ga
carrier
effort
made
incorpor
clinic
epidemiolog
featur
acut
pharyng
score
system
attempt
predict
probabl
particular
ill
caus
ga
clinic
score
system
help
identifi
patient
low
risk
infect
ga
throat
cultur
radt
usual
unnecessari
sign
symptom
group
betahemolyt
streptococc
nongroup
betahemolyt
streptococc
pharyng
overlap
broadli
howev
clinic
diagnosi
group
betahemolyt
streptococc
pharyng
made
accuraci
even
gerber
experienc
physician
guidelin
infecti
diseas
societi
america
idsa
american
academi
pediatr
american
heart
associ
indic
microbiolog
confirm
throat
cultur
radt
requir
diagnosi
group
betahemolyt
streptococc
pharyng
new
practic
guidelin
center
diseas
control
prevent
cdc
american
academi
famili
physician
aafp
american
colleg
physiciansamerican
societi
intern
medicin
acpasim
recommend
use
clinic
algorithm
without
microbiolog
confirm
accept
approach
diagnosi
group
betahemolyt
streptococc
pharyng
adult
although
goal
algorithmbas
strategi
reduc
inappropri
use
antibiot
adult
pharyng
concern
use
would
result
administr
antimicrobi
treatment
unaccept
larg
number
adult
nongroup
betahemolyt
streptococc
pharyng
author
cdcaafpacpasim
guidelin
suggest
prospect
studi
conduct
compar
particular
strategi
strategi
term
relev
patient
outcom
cost
mcisaac
et
al
perform
retrospect
analysi
assess
impact
six
differ
guidelin
includ
idsa
cdcaafpacipasim
guidelin
identif
treatment
group
betahemolyt
streptococc
pharyng
children
adult
guidelin
recommend
select
use
radt
throat
cultur
treatment
base
posit
test
result
significantli
reduc
inappropri
use
antibiot
adult
contrast
empir
strategi
propos
cdcaafpacipasim
guidelin
result
administr
unnecessari
antibiot
unaccept
larg
number
adult
abandon
concept
treatment
laboratori
confirm
ga
adult
pharyng
idsa
guidelin
addit
prospect
studi
need
perform
compar
empir
laboratorybas
strategi
term
relev
patient
outcom
cost
cultur
specimen
obtain
throat
swab
sheep
blood
agar
plate
standard
laboratori
procedur
microbiolog
confirm
clinic
diagnosi
acut
group
betahemolyt
streptococc
pharyng
perform
correctli
singl
throat
swab
sensit
detect
presenc
ga
pharynx
sever
variabl
may
affect
accuraci
throat
cultur
result
one
import
manner
swab
obtain
throat
swab
specimen
obtain
surfac
tonsil
tonsillar
fossa
posterior
pharyng
wall
area
pharynx
mouth
accept
site
touch
cultur
procedur
even
appropri
collect
specimen
falseneg
result
may
obtain
patient
receiv
antibiot
throat
swab
taken
anaerob
incub
use
select
cultur
media
report
increas
sensit
throat
cultur
data
regard
impact
atmospher
incub
cultur
media
conflict
howev
absenc
definit
benefit
increas
cost
effort
associ
anaerob
incub
select
cultur
media
difficult
justifi
particularli
physician
process
throat
cultur
offic
durat
incub
anoth
variabl
affect
yield
throat
cultur
plate
cultur
incub
hour
read
addit
overnight
incub
room
temperatur
would
identifi
consider
number
posit
throat
cultur
howev
would
otherwis
identifi
armengol
et
al
found
posit
confirmatori
throat
cultur
obtain
patient
pharyng
neg
radt
neg
hour
incub
posit
hour
although
initi
therapeut
decis
may
made
basi
overnight
cultur
advis
examin
plate
neg
hour
hour
clinic
signific
number
coloni
ga
present
throat
cultur
plate
controversi
patient
bona
fide
acut
group
betahemolyt
streptococc
pharyng
like
coloni
ga
cultur
plate
patient
ga
carrier
much
overlap
coloni
count
howev
patient
acut
infect
ga
ga
carrier
permit
differenti
basi
degre
posit
probabl
wide
use
test
differenti
ga
betahemolyt
streptococci
physician
offic
bacitracin
disk
test
test
provid
presumpt
identif
base
observ
greater
ga
show
zone
inhibit
around
disk
contain
unit
bacitracin
wherea
nonga
inhibit
bacitracin
altern
highli
specif
method
differenti
ga
betahemolyt
streptococci
detect
groupspecif
cell
wall
carbohydr
antigen
directli
isol
bacteri
coloni
commerci
kit
employ
groupspecif
antisera
avail
purpos
test
appropri
use
clinic
microbiolog
laboratori
physician
perform
throat
cultur
would
find
difficult
justifi
addit
expens
minim
improv
accuraci
serogroup
betahemolyt
streptococci
would
provid
bacitracin
disk
test
major
disadvantag
cultur
specimen
obtain
throat
swab
blood
agar
plate
delay
obtain
cultur
result
radt
develop
identif
ga
directli
throat
swab
although
radt
expens
blood
agar
plate
cultur
advantag
offer
tradit
procedur
speed
provid
gerber
result
rapid
identif
treatment
patient
group
betahemolyt
streptococc
pharyng
reduc
risk
spread
ga
allow
patient
return
school
work
sooner
speed
clinic
improv
addit
certain
environ
eg
emerg
depart
use
radt
shown
increas
significantli
number
patient
appropri
treat
group
betahemolyt
streptococc
pharyng
compar
use
throat
cultur
current
avail
radt
specif
greater
compar
blood
agar
plate
cultur
falseposit
test
result
unusu
therapeut
decis
made
confid
basi
posit
radt
result
sensit
radt
although
suggest
mani
falseneg
radt
result
occur
patient
ga
carrier
shown
larg
proport
patient
falseneg
radt
result
truli
infect
ga
first
radt
use
latex
agglutin
methodolog
rel
insensit
unclear
end
point
subsequ
test
base
enzym
immunoassay
techniqu
sharpli
defin
end
point
increas
sensit
recent
radt
use
optic
immunoassay
chemiluminesc
dna
probe
develop
test
may
sensit
radt
perhap
even
sensit
blood
agar
plate
cultur
conflict
limit
data
optic
immunoassay
commerci
avail
radt
howev
advisori
group
recommend
physician
elect
use
radt
children
adolesc
without
cultur
backup
neg
result
show
practic
radt
sensit
throat
cultur
current
two
import
issu
regard
use
radt
diagnosi
group
betahemolyt
streptococc
pharyng
rel
sensit
differ
test
whether
radt
sensit
enough
mitig
need
perform
throat
cultur
patient
neg
test
result
studi
evalu
sensit
radt
compar
perform
singl
type
radt
standard
cultur
consider
variabl
studi
design
cultur
techniqu
difficult
compar
sensit
radt
determin
one
studi
sensit
anoth
radt
determin
differ
studi
rel
sensit
differ
radt
determin
direct
comparison
date
four
direct
comparison
differ
radt
report
english
literatur
one
letter
editor
rel
sensit
differ
radt
establish
studi
investig
perform
radt
current
use
clinic
practic
armengol
et
al
attempt
valid
sensit
specif
radt
use
practic
abandon
confirmatori
throat
cultur
neg
radt
result
studi
perform
three
winter
season
use
onsit
physician
offic
laboratori
pediatr
group
practic
found
radt
sensit
approxim
compar
singl
blood
agar
plate
cultur
investig
conclud
sensit
particular
radt
low
consid
abandon
confirmatori
throat
cultur
practic
contrast
may
pichichero
review
experi
radt
differ
pediatr
group
practic
januari
june
period
radt
perform
neg
confirmatori
blood
agar
plate
cultur
perform
neg
test
determin
neg
radt
result
posit
throat
cultur
cost
analysi
show
elimin
confirmatori
throat
cultur
neg
radt
result
could
produc
substanti
save
practic
patient
investig
conclud
cultur
confirm
neg
radt
result
may
necessari
circumst
neither
blood
agar
plate
cultur
radt
differenti
accur
individu
bona
fide
group
betahemolyt
streptococc
pharyng
asymptomat
ga
carrier
intercurr
viral
pharyng
facilit
howev
withhold
antibiot
patient
sore
throat
whose
cultur
radt
neg
extrem
import
estim
million
visit
primari
care
provid
adult
complain
sore
throat
year
unit
state
antibiot
prescrib
visit
although
recent
trend
suggest
declin
use
antibiot
children
adolesc
pharyng
children
adolesc
seen
primari
care
provid
pharyng
receiv
prescript
antibiot
antistreptococc
antibodi
titer
reflect
past
present
immunolog
event
valu
diagnosi
acut
group
betahemolyt
streptococc
pharyng
valuabl
confirm
prior
group
betahemolyt
streptococc
infect
patient
suspect
acut
rheumat
fever
poststreptococc
acut
glomerulonephr
antistreptococc
antibodi
titer
also
help
prospect
epidemiolog
studi
tri
differenti
patient
acut
group
betahemolyt
streptococc
infect
patient
ga
carrier
asymptomat
patient
confirm
posit
throat
cultur
complet
cours
appropri
antimicrobi
therapi
ga
carrier
followup
throat
cultur
radt
routin
indic
asymptomat
patient
complet
cours
antibiot
therapi
ga
specif
situat
howev
followup
throat
cultur
radt
asymptomat
individu
perform
patient
histori
rheumat
fever
routin
followup
test
test
also
consid
patient
develop
acut
pharyng
outbreak
either
acut
rheumat
fever
poststreptococc
acut
glomerugerb
lonephr
outbreak
group
betahemolyt
streptococc
pharyng
close
semiclos
commun
antimicrobi
therapi
indic
individu
symptomat
pharyng
presenc
ga
throat
confirm
either
throat
cultur
radt
situat
clinic
epidemiolog
evid
result
high
index
suspicion
antimicrobi
therapi
initi
await
laboratori
confirm
provid
therapi
discontinu
diagnosi
group
betahemolyt
streptococc
pharyng
confirm
laboratori
test
earli
initi
antimicrobi
therapi
group
betahemolyt
streptococc
pharyng
result
shorten
clinic
cours
ill
group
betahemolyt
streptococc
pharyng
usual
selflimit
diseas
howev
sign
symptom
resolv
spontan
within
day
onset
even
without
antimicrobi
therapi
addit
initi
antimicrobi
therapi
delay
day
onset
symptom
still
prevent
occurr
acut
rheumat
fever
flexibl
initi
antimicrobi
therapi
evalu
individu
patient
presum
group
betahemolyt
streptococc
pharyng
numer
antimicrobi
agent
shown
effect
treatment
group
betahemolyt
streptococc
pharyng
includ
penicillin
congen
eg
ampicillin
amoxicillin
numer
cephalosporin
macrolid
clindamycin
select
antimicrobi
treatment
group
betahemolyt
streptococc
pharyng
import
consid
efficaci
safeti
antimicrobi
spectrum
narrow
versu
broad
dose
schedul
complianc
cost
base
consider
sever
advisori
bodi
recommend
penicillin
treatment
choic
infect
although
problem
increas
antimicrobi
resist
among
bacteria
one
import
current
infecti
diseas
issu
ga
never
develop
resist
penicillin
cephalosporin
shown
increas
penicillin
minim
inhibitori
concentr
least
decad
amoxicillin
often
use
place
oral
penicillin
v
young
children
efficaci
appear
equal
choic
relat
primarili
accept
tast
amoxicillin
suspens
oral
administ
erythromycin
indic
patient
allerg
penicillin
macrolid
clarithromycin
azithromycin
also
effect
firstgener
cephalosporin
also
accept
penicillinallerg
patient
manifest
immediatetyp
hypersensit
blactam
antibiot
casey
pichichero
present
metaanalysi
clinic
trial
perform
cephalosporin
compar
penicillin
treatment
group
betahemolyt
streptococc
pharyng
base
analysi
conclud
cephalosporin
ad
treatment
choic
group
betahemolyt
streptococc
tonsillopharyng
report
sever
major
flaw
howev
make
imposs
accept
valid
conclus
although
use
cephalosporin
group
betahemolyt
streptococc
pharyng
could
reduc
number
patient
mere
chronic
carrier
continu
harbor
organ
throat
complet
therapi
econom
ecolog
cost
involv
would
make
pyrrhic
victori
advoc
use
cephalosporin
drug
choic
streptococc
pharyng
penicillin
stood
test
time
satisfactorili
decad
compel
reason
eg
narrow
antimicrobi
spectrum
inexpens
cost
impress
safeti
profil
continu
recommend
drug
choic
oral
antibiot
must
administ
day
achiev
maxim
pharyng
erad
rate
ga
report
sever
antimicrobi
agent
includ
clarithromycin
cefuroxim
cefixim
ceftibuten
cefdinir
cefpodoxim
azithromycin
effect
erad
ga
pharynx
administ
fewer
day
mani
studi
shortcours
therapi
seriou
methodolog
flaw
howev
rais
question
valid
conclus
addit
spectra
antibiot
much
broader
penicillin
even
administ
short
cours
expens
addit
studi
need
shortcours
regimen
recommend
attempt
treat
group
betahemolyt
streptococc
pharyng
singl
daili
dose
penicillin
unsuccess
recent
year
investig
shown
sever
antimicrobi
agent
includ
azithromycin
cefadroxil
cefixim
ceftibuten
cefpodoxim
cefprozil
cefdinir
effect
erad
pharyng
streptococci
given
singl
daili
dose
agent
expens
howev
broad
spectra
activ
compar
penicillin
preliminari
investig
shown
oncedaili
amoxicillin
therapi
effect
treatment
group
betahemolyt
streptococc
pharyng
confirm
addit
investig
oncedaili
amoxicillin
therapi
low
cost
rel
narrow
spectrum
could
becom
altern
regimen
treatment
group
betahemolyt
streptococc
pharyng
antimicrobi
therapi
group
betahemolyt
streptococc
pharyng
may
given
oral
parenter
tabl
give
recommend
sever
antimicrobi
prove
effect
treatment
group
betahemolyt
streptococc
pharyng
intramuscular
benzathin
penicillin
g
prefer
patient
unlik
complet
full
cours
oral
therapi
antimicrobi
resist
signific
issu
treatment
group
betahemolyt
streptococc
pharyng
unit
state
never
clinic
isol
ga
document
resist
penicillin
anywher
world
although
geograph
area
rel
high
level
resist
macrolid
antibiot
rate
gerber
macrolid
resist
among
isol
ga
unit
state
gener
remain
low
less
investig
antibiot
resist
pattern
pharyng
isol
invas
isol
ga
obtain
state
district
columbia
isol
determin
macrolid
resist
higher
resist
rate
occasion
report
howev
nine
percent
pharyng
invas
ga
strain
collect
san
francisco
report
macrolid
resist
martin
et
al
longitudin
investig
group
betahemolyt
streptococc
diseas
singl
elementari
school
pittsburgh
pennsylvania
found
isol
ga
collect
octob
may
resist
erythromycin
none
resist
clindamycin
molecular
type
indic
outbreak
due
singl
strain
ga
addit
randomli
select
isol
ga
obtain
commun
april
june
resist
erythromycin
tanz
et
al
report
result
prospect
multicent
communitybas
surveil
pharyng
isol
ga
recov
children
year
old
three
success
respiratori
season
period
macrolid
resist
rate
among
pharyng
ga
unit
state
less
stabl
clindamycin
resist
found
isol
studi
period
vari
studi
year
evid
wide
dissemin
spe
cific
macrolideresist
clone
increas
clindamycin
resist
increas
erythromycin
minim
inhibitori
concentr
studi
period
howev
consider
geograph
variabl
macrolid
resist
rate
studi
year
yeartoyear
variabl
individu
studi
site
although
result
reassur
clinician
need
awar
local
resist
rate
futur
signific
increas
rate
macrolid
resist
among
ga
strain
may
necessari
reconsid
recommend
treatment
group
betahemolyt
streptococc
pharyng
penicillinallerg
patient
primari
reason
identifi
either
group
c
group
g
streptococcu
caus
acut
pharyng
initi
antimicrobi
therapi
may
mitig
clinic
cours
infect
current
convinc
evid
howev
control
studi
clinic
respons
antimicrobi
therapi
patient
acut
pharyng
either
group
c
group
g
streptococcu
isol
pharynx
one
elect
treat
either
group
c
group
g
streptococc
pharyng
treatment
similar
group
betahemolyt
streptococc
pharyng
penicillin
antimicrobi
agent
choic
group
betahemolyt
streptococc
pharyng
associ
suppur
nonsuppur
complic
suppur
complic
result
spread
ga
adjac
structur
includ
peritonsillar
abscess
retropharyng
abscess
cervic
lymphaden
sinus
otiti
media
mastoid
antimicrobi
agent
avail
suppur
complic
group
betahemolyt
streptococc
pharyng
common
howev
antimicrobi
therapi
reduc
greatli
frequenc
complic
acut
rheumat
fever
acut
poststreptococc
glomerulonephr
poststreptococc
reactiv
arthriti
recogn
nonsuppur
sequela
group
betahemolyt
streptococc
pharyng
acut
rheumat
fever
occur
episod
group
betahemolyt
streptococc
pharyng
usual
latent
period
group
betahemolyt
streptococc
infect
skin
appropri
antimicrobi
therapi
begun
within
day
onset
pharyng
prevent
complic
contrast
acut
rheumat
fever
acut
poststreptococc
glomerulonephr
occur
group
betahemolyt
streptococc
infect
either
pharynx
skin
seem
prevent
antimicrobi
therapi
anteced
group
betahemolyt
streptococc
infect
latent
period
glomerulonephr
week
skin
infect
day
upper
respiratori
tract
infect
poststreptococc
reactiv
arthriti
similar
postinfecti
arthritid
relationship
entiti
acut
rheumat
fever
still
unclear
gerber
acut
glomerulonephr
report
extrem
unusu
complic
group
c
streptococc
pharyng
causal
relationship
group
g
streptococc
pharyng
acut
glomerulonephr
establish
acut
rheumat
fever
describ
complic
either
group
c
group
g
streptococc
pharyng
antimicrobi
treatment
failur
group
betahemolyt
streptococc
pharyng
tradit
classifi
either
clinic
bacteriolog
failur
signific
clinic
treatment
failur
usual
defin
persist
recurr
sign
symptom
suggest
group
betahemolyt
streptococc
pharyng
difficult
determin
howev
group
betahemolyt
streptococc
pharyng
selflimit
ill
even
without
antimicrobi
therapi
addit
without
repeat
isol
infect
strain
ga
ie
true
bacteriolog
treatment
failur
particularli
difficult
determin
clinic
signific
persist
recurr
sign
symptom
suggest
group
betahemolyt
streptococc
pharyng
bacteriolog
treatment
failur
classifi
either
true
appar
failur
true
bacteriolog
failur
refer
inabl
erad
specif
strain
ga
caus
acut
episod
pharyng
complet
cours
appropri
antimicrobi
therapi
appar
bacteriolog
treatment
failur
reflect
varieti
circumst
appar
bacteriolog
treatment
failur
patient
ga
carrier
ie
patient
ga
upper
respiratori
tract
without
ill
immunolog
respons
ga
carrier
unlik
spread
ga
close
contact
low
risk
develop
suppur
nonsuppur
complic
winter
spring
temper
climat
asymptomat
schoolag
children
ga
carrier
appar
bacteriolog
failur
also
occur
newli
acquir
ga
isol
mistaken
origin
infect
strain
ga
infect
strain
ga
erad
rapidli
reacquir
complianc
antimicrobi
therapi
poor
although
specif
reason
true
bacteriolog
treatment
failur
determin
sever
explan
propos
suggest
ga
may
becom
resist
penicillin
howev
evid
support
hypothesi
penicillinresist
strain
ga
identifi
also
suggest
strain
ga
develop
penicillin
toler
ie
discord
concentr
penicillin
requir
inhibit
kill
organ
howev
role
penicillin
toler
true
bacteriolog
treatment
failur
never
establish
also
suggest
speci
bacteria
present
normal
pharyng
flora
contribut
true
bacteriolog
failur
either
enhanc
colon
growth
ga
upper
respiratori
tract
produc
blactamas
inactiv
penicillin
precis
role
organ
determin
yet
howev
routin
throat
cultur
radt
asymptomat
individu
complet
antibiot
therapi
group
betahemolyt
streptococc
pharyng
gener
indic
interpret
posit
throat
cultur
radt
cours
treatment
may
difficult
even
patient
remain
symptomat
possibl
distinguish
persist
carriag
persist
recurr
infect
circumst
mani
clinician
elect
administ
second
cours
antimicrobi
physician
suspect
ping
pong
spread
associ
multipl
repeat
episod
group
betahemolyt
streptococc
infect
famili
simultan
cultur
famili
contact
treatment
person
whose
cultur
posit
may
help
credibl
evid
famili
pet
reservoir
ga
contribut
famili
spread
patient
repeat
episod
acut
pharyng
associ
posit
throat
cultur
radt
common
difficult
problem
practic
physician
fundament
question
must
address
whether
patient
experienc
repeat
episod
bona
fide
group
betahemolyt
streptococc
pharyng
ga
carrier
experienc
repeat
episod
viral
pharyng
latter
situat
consider
common
former
patient
like
ga
carrier
clinic
epidemiolog
find
suggest
viral
etiolog
littl
clinic
respons
appropri
antimicrobi
therapi
throat
cultur
radt
also
posit
episod
pharyng
serolog
respons
ga
extracellular
antigen
eg
antistreptolysin
antidnas
b
contrast
patient
repeat
episod
acut
pharyng
associ
posit
throat
cultur
radt
ga
like
experienc
repeat
episod
bona
fide
group
betahemolyt
streptococc
pharyng
clinic
epidermiolog
find
suggest
group
betahemolyt
streptococc
pharyng
etiolog
demonstr
clinic
respons
appropri
antimicrobi
therapi
throat
cultur
radt
neg
episod
pharyng
serolog
respons
ga
extracellular
antigen
determin
patient
experienc
repeat
episod
bona
fide
group
betahemolyt
streptococc
pharyng
suggest
prophylact
oral
penicillin
v
efficaci
regimen
never
prove
howev
antimicrobi
prophylaxi
recommend
except
prevent
recurr
rheumat
fever
patient
experienc
previou
episod
rheumat
fever
tonsillectomi
may
consid
rare
patient
whose
symptomat
episod
diminish
frequenc
time
altern
explan
recurr
group
betahemolyt
streptococc
pharyng
evid
tonsillectomi
shown
benefici
rel
small
group
patient
howev
benefit
expect
rel
shortliv
